RBC Adjusts Korro Bio's PT to $95 From $105, Keeps Outperform Rating, Speculative Risk
RBC Adjusts Korro Bio's PT to $95 From $105, Keeps Outperform Rating, Speculative Risk
RBC将科罗生物的目标股价从105美元调整为95美元，维持跑赢大市评级，但风险较高。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间